Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-15, Stock:PFE, The news for the past five days is as follows:
2019-02-08: NEWS1: This Gene Therapy Stock Could Soon Hit The Auction Block — Here&apos;s Why.NEWS2: Notable ETF Inflow Detected - SPYG, GOOG, GOOGL, PFE.NEWS3: Notable ETF Inflow Detected - SPYG, GOOG, GOOGL, PFE.NEWS4: Pfizer Japan recalls high blood pressure drug over cancer-causing impurity.NEWS5: Health Care Sector Update for 02/08/2019: APOP, SGEN, MBOT, JNJ, PFE, ABT, MRK, AMGN.NEWS6: Health Care Sector Update for 02/08/2019: APOP, SGEN, MBOT, JNJ, PFE, ABT, MRK, AMGN.NEWS7: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS8: Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs.NEWS9: Dow 30 Stock Roundup: Disney Earnings Impress, Pfizer's Cancer Drug Gets CHMP Nod.NEWS10: Pfizer Japan recalls high blood pressure drug Amvalo due to carcinogen.NEWS11: Buying the Dow Stocks With the Highest Dividends Is a Winning Strategy.NEWS12: What Solid Biosciences' First Failure Means for Sarepta Therapeutics.NEWS13: What Solid Biosciences' First Failure Means for Sarepta Therapeutics.
2019-02-11: NEWS1: FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma.NEWS2: After Hours Most Active for Feb 11, 2019 :  SNAP, BAC, ELAN, FDC, PFE, MGM, FOMX, EMB, FB, EBAY, JBLU, CELG.NEWS3: After Hours Most Active for Feb 11, 2019 :  SNAP, BAC, ELAN, FDC, PFE, MGM, FOMX, EMB, FB, EBAY, JBLU, CELG.NEWS4: Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer.NEWS5: Stocks Start Week of Trade Talks on Muted Note: Markets Wrap.NEWS6: Stocks making the biggest moves midday: Avis Budget Group, Pfizer, Tesla & more.NEWS7: Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake.NEWS8: Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake.NEWS9: See Which Of The Latest 13F Filers Holds Pfizer.NEWS10: See Which Of The Latest 13F Filers Holds Pfizer.NEWS11: Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake.NEWS12: Dow 30 Stock Roundup: Disney Earnings Impress, Pfizer's Cancer Drug Gets CHMP Nod.NEWS13: Dow 30 Stock Roundup: Disney Earnings Impress, Pfizer's Cancer Drug Gets CHMP Nod.NEWS14: Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs.NEWS15: Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs.
2019-02-12: NEWS1: Bristol-Myers' Sprycel Gets European Nod for Label Expansion.NEWS2: Pfizer or Eli Lilly: Who Is Expected to Report Higher EPS Growth?.NEWS3: Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?.NEWS4: What Analysts Recommend for Pfizer and Eli Lilly in February.NEWS5: Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review.NEWS6: Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review.NEWS7: Stock Market News For Feb 12, 2019.NEWS8: Stock Market News For Feb 12, 2019.NEWS9: Alnylam Pharmaceuticals Is Launched and Ready for More.NEWS10: Alnylam Pharmaceuticals Is Launched and Ready for More.NEWS11: Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review.NEWS12: Better Buy: Gilead Sciences vs. Pfizer.NEWS13: Better Buy: Gilead Sciences vs. Pfizer.NEWS14: Stock Market News For Feb 12, 2019.NEWS15: Health Care Sector Update for 02/12/2019: KMDA, GILD, MDGS, JNJ, PFE, MRK, ABT, AMGN.NEWS16: Health Care Sector Update for 02/12/2019: KMDA, GILD, MDGS, JNJ, PFE, MRK, ABT, AMGN.NEWS17: Better Buy: Gilead Sciences vs. Pfizer.NEWS18: Merck, Pfizer combo treatment boosts kidney cancer survival.
2019-02-13: NEWS1: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS2: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS3: Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4.NEWS4: Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4.NEWS5: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS6: Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4.NEWS7: What Are the Key Growth Drivers for Pfizer in Fiscal 2019?.NEWS8: Health Care Sector Update for 02/13/2019: BABY, TEVA, EXEL, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Health Care Sector Update for 02/13/2019: BABY, TEVA, EXEL, JNJ, PFE, ABT, MRK, AMGN.NEWS10: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2019.NEWS11: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2019.NEWS12: Allergan plc. (AGN) Ex-Dividend Date Scheduled for February 14, 2019.NEWS13: Allergan plc. (AGN) Ex-Dividend Date Scheduled for February 14, 2019.NEWS14: Pfizer and Eli Lilly: How Dividends and Tax Rates Stack Up.NEWS15: Pfizer or Eli Lilly: Who Is Controlling Expenses Better?.NEWS16: Dogs of the Dow and a 3 Top Dogs Strategy.NEWS17: Bristol-Myers' Sprycel Gets European Nod for Label Expansion.NEWS18: Bristol-Myers' Sprycel Gets European Nod for Label Expansion.
2019-02-14: NEWS1: Bayer stresses drug's tolerability in bid for prostate cancer market.NEWS2: The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial.NEWS3: Pfizer still holds the lead in the erectile dysfunction market even as Viagra sales falter.

Answer: Rise